Europe Tardive Dyskinesia Market Size & Outlook, 2026-2034

Europe Tardive Dyskinesia Market Insights

As highlighted in Reed Intelligence analysis, the Europe Tardive Dyskinesia Market, valued at USD 938.74 Million in 2025, is estimated to achieve USD 2268.32 Million by 2034.
The market is estimated to grow at a CAGR of 10.28% spanning 2026 to 2034.
By market size, VMAT2 Inhibitors led the Drug Class category in 2025.
The Drug Class segment led by Dopamine Modulators is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.

Other Key Findings

Europe represented 29.52% of the global Tardive Dyskinesia Market size in 2025.
By 2034, United States is estimated to hold the largest position in the global market in terms of size.
Benelux is estimated to remain the fastest-growing market in Europe, advancing to USD 119.76 Million by 2034.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 938.74 Million
Market Size In 2034	USD 2268.32 Million
Largest segment	VMAT2 Inhibitors
Units	Revenue in USD Million
CAGR	10.28% (2026-2034)
Segmnetation Covered
Europe	Germany United Kingdom France Italy Spain Russia Nordic Benelux
Drug Class	VMAT2 Inhibitors Dopamine Modulators Novel Neuromodulators Supportive Therapies
Distribution Channel	Hospital Pharmacies Retail Pharmacies Specialty Pharmacies Online Pharmacies
End Use	Hospitals Specialty Clinics Homecare Settings Rehabilitation Centers
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Europe Tardive Dyskinesia Market Country 2026-2034 (USD Million)

Europe	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Germany	XX.x	XX.x	XX.x	237.78	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
United Kingdom	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
France	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Italy	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Spain	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Russia	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Nordic	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Benelux	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Europe Tardive Dyskinesia Market Drug Class 2026-2034 (USD Million)

Drug Class	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
VMAT2 Inhibitors	XX.x	XX.x	XX.x	432.95	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Dopamine Modulators	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Novel Neuromodulators	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Supportive Therapies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Europe Tardive Dyskinesia Market Distribution Channel 2026-2034 (USD Million)

Distribution Channel	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospital Pharmacies	XX.x	XX.x	XX.x	408.26	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Retail Pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty Pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Online Pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Europe Tardive Dyskinesia Market End Use 2026-2034 (USD Million)

End Use	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	375.5	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Homecare Settings	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Rehabilitation Centers	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.